TMEM242

Summary

TMEM242 (transmembrane protein 242, HGNC:17206) is a protein-coding gene on chromosome 6q25.3, encoding Transmembrane protein 242 (Q9NWH2). Scaffold protein that participates in the c-ring assembly of mitochondrial ATP synthase (F(1)F(0) ATP synthase or complex V) by facilitating the membrane insertion and oligomer formation of the subunit c/ATP5MC3. It is a selective cancer dependency (DepMap: 19.0% of cell lines).

Involved in mitochondrial proton-transporting ATP synthase complex assembly. Located in mitochondrial inner membrane.

Source: NCBI Gene 729515 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 22 total — 1 pathogenic
• Phenotypes (HPO): 1
• Cancer dependency (DepMap): dependent in 19.0% of screened cell lines
• MANE Select transcript: NM_018452

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17206
Approved symbol	TMEM242
Name	transmembrane protein 242
Location	6q25.3
Locus type	gene with protein product
Status	Approved
Aliases	BM033
Ensembl gene	ENSG00000215712
Ensembl biotype	protein_coding
OMIM	620721
Entrez	729515

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000367144, ENST00000400788, ENST00000945919

RefSeq mRNA: 1 — MANE Select: NM_018452 NM_018452

CCDS: CCDS43519

Canonical transcript exons

ENST00000400788 — 4 exons

Exon	Start	End
ENSE00001741276	157322705	157322805
ENSE00001791927	157318782	157318919
ENSE00001904676	157289025	157292999
ENSE00003896557	157323412	157323519

Expression profiles

Bgee: expression breadth ubiquitous, 262 present calls, max score 91.92.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.5164 / max 229.6578, expressed in 1804 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
76361	15.8007	1797
76362	0.7157	472

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	91.92	gold quality
vena cava	UBERON:0004087	91.05	gold quality
decidua	UBERON:0002450	88.08	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	86.82	gold quality
heart right ventricle	UBERON:0002080	86.75	gold quality
pons	UBERON:0000988	86.71	gold quality
pericardium	UBERON:0002407	86.26	gold quality
body of tongue	UBERON:0011876	85.04	gold quality
prefrontal cortex	UBERON:0000451	84.43	gold quality
pharyngeal mucosa	UBERON:0000355	84.09	gold quality
biceps brachii	UBERON:0001507	83.78	gold quality
synovial joint	UBERON:0002217	83.49	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	83.08	gold quality
parotid gland	UBERON:0001831	83.03	silver quality
cardia of stomach	UBERON:0001162	82.90	silver quality
cardiac ventricle	UBERON:0002082	82.83	gold quality
subthalamic nucleus	UBERON:0001906	82.78	gold quality
saphenous vein	UBERON:0007318	82.75	gold quality
heart left ventricle	UBERON:0002084	82.73	gold quality
tibialis anterior	UBERON:0001385	82.61	silver quality
muscle of leg	UBERON:0001383	82.38	gold quality
thoracic aorta	UBERON:0001515	82.24	gold quality
gastrocnemius	UBERON:0001388	82.23	gold quality
ascending aorta	UBERON:0001496	82.22	gold quality
oocyte	CL:0000023	82.20	gold quality
lateral nuclear group of thalamus	UBERON:0002736	82.14	silver quality
mammalian vulva	UBERON:0000997	82.04	gold quality
frontal cortex	UBERON:0001870	82.04	gold quality
left coronary artery	UBERON:0001626	82.03	gold quality
descending thoracic aorta	UBERON:0002345	82.02	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.27

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

124 targeting TMEM242, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-664B-3P	99.84	71.65	3590

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 19.0% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 1)

• TMEM70 and TMEM242 help to assemble the rotor ring of human ATP synthase and interact with assembly factors for complex I. (PMID:33753518)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	tmem242	ENSDARG00000037070
mus_musculus	Tmem242	ENSMUSG00000004945
rattus_norvegicus	Tmem242	ENSRNOG00000016973
drosophila_melanogaster	CG11699	FBGN0030311

Protein

Protein identifiers

Transmembrane protein 242 — Q9NWH2 (reviewed: Q9NWH2)

All UniProt accessions (2): Q9NWH2, Q5T2S1

UniProt curated annotations — full annotation on UniProt →

Function. Scaffold protein that participates in the c-ring assembly of mitochondrial ATP synthase (F(1)F(0) ATP synthase or complex V) by facilitating the membrane insertion and oligomer formation of the subunit c/ATP5MC3. Participates in the incorporation of the c-ring into vestigial complexes. Additionally influences the incorporation of subunits MT-ATP6, MT-ATP8, ATP5MJ, and ATP5MK in the ATP synthase.

Subunit / interactions. Interacts with the core subunits NDUFAF1, ECSIT and ACAD9 of the MCIA complex. Interacts with ATP5MC3, NDUFC2, TMEM70, MT-ND2 and MT-ND3.

Subcellular location. Mitochondrion inner membrane.

Similarity. Belongs to the TMEM242 family.

RefSeq proteins (1): NP_060922* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009792	TMEM242	Family

Pfam: PF07096

UniProt features (7 total): topological domain 3, transmembrane region 2, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NWH2-F1	72.63	0.21

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 151 (showing top): GOBP_MITOCHONDRIAL_RESPIRATORY_CHAIN_COMPLEX_ASSEMBLY, HEIDENBLAD_AMPLICON_8Q24_DN, chr6q25, CADWELL_ATG16L1_TARGETS_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP, GOCC_MITOCHONDRIAL_ENVELOPE, NKX3A_01, GOCC_ORGANELLE_INNER_MEMBRANE, MATSUDA_NATURAL_KILLER_DIFFERENTIATION, GOCC_ORGANELLE_ENVELOPE, MIKKELSEN_ES_ICP_WITH_H3K4ME3, MIKKELSEN_NPC_ICP_WITH_H3K4ME3, PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_UP, GOBP_PROTON_TRANSPORTING_TWO_SECTOR_ATPASE_COMPLEX_ASSEMBLY, ALKBH3_TARGET_GENES

GO Biological Process (1): mitochondrial proton-transporting ATP synthase complex assembly (GO:0033615)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
mitochondrion	1
mitochondrial respiratory chain complex assembly	1
proton-transporting ATP synthase complex assembly	1
binding	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1
cellular anatomical structure	1

Protein interactions and networks

STRING

410 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM242	TMEM70	Q9BUB7	699
TMEM242	SERAC1	Q96JX3	606
TMEM242	URB1	O60287	562
TMEM242	TULP4	Q9NRJ4	526
TMEM242	SCAF8	Q9UPN6	512
TMEM242	OXLD1	Q5BKU9	497
TMEM242	SIAE	Q9HAT2	490
TMEM242	PIGBOS1	A0A0B4J2F0	490
TMEM242	HEATR1	Q9H583	486
TMEM242	GTF2H5	Q6ZYL4	474
TMEM242	ANTKMT	Q9BQD7	457
TMEM242	LYRM9	A8MSI8	453
TMEM242	TFB1M	Q8WVM0	449
TMEM242	INTS15	Q96N11	447
TMEM242	ZDHHC14	Q8IZN3	444
TMEM242	CSKMT	A8MUP2	444

IntAct

125 interactions, top by confidence:

A	B	Type	Score
GGT7	TMEM242	psi-mi:“MI:0915”(physical association)	0.720
TMEM242	GGT7	psi-mi:“MI:0915”(physical association)	0.720
RNF5	TMEM242	psi-mi:“MI:0915”(physical association)	0.560
TMEM242	RNF5	psi-mi:“MI:0915”(physical association)	0.560
ATP6V0B	TMEM242	psi-mi:“MI:0915”(physical association)	0.560
MFSD6	TMEM242	psi-mi:“MI:0915”(physical association)	0.560
SLC30A3	TMEM242	psi-mi:“MI:0915”(physical association)	0.560
	TMEM242	psi-mi:“MI:0915”(physical association)	0.560
TMEM242	CYB561	psi-mi:“MI:0915”(physical association)	0.560
TMBIM1	TMEM242	psi-mi:“MI:0915”(physical association)	0.560
TMEM242	AQP6	psi-mi:“MI:0915”(physical association)	0.560
SLC19A3	TMEM242	psi-mi:“MI:0915”(physical association)	0.560
TMEM242	MSMO1	psi-mi:“MI:0915”(physical association)	0.560
GHITM	TMEM242	psi-mi:“MI:0915”(physical association)	0.560
PLP1	TMEM242	psi-mi:“MI:0915”(physical association)	0.560
SYNJ2BP	TMEM242	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (62): TMEM242 (Two-hybrid), TMEM242 (Two-hybrid), TMEM242 (Affinity Capture-MS), TMEM242 (Affinity Capture-MS), TMEM242 (Affinity Capture-MS), TMEM242 (Affinity Capture-RNA), TMEM242 (Affinity Capture-RNA), TMEM242 (Positive Genetic), TMEM242 (Two-hybrid), TMEM242 (Two-hybrid), TMEM242 (Two-hybrid), TMEM242 (Two-hybrid), TMEM242 (Two-hybrid), TMEM242 (Two-hybrid), TMEM242 (Two-hybrid)

ESM2 similar proteins: A1L2P2, A1XQR7, A8E7D3, A8MTT3, L0R6Q1, O48832, O64497, O82803, P11951, P13183, P14790, P24311, P43883, P46270, P80977, Q148H0, Q1LUK1, Q1MTD4, Q1RMH3, Q21154, Q28EM2, Q2ACH7, Q41112, Q4V8S3, Q5BKW8, Q5CZQ0, Q5R987, Q5XFV8, Q5XKP0, Q63ZZ0, Q68EV8, Q7SGT7, Q7YRK0, Q7YRK1, Q810Q5, Q84K90, Q8BH51, Q8BTE5, Q8R404, Q8VCR3

Diamond homologs: Q4V8S3, Q5R987, Q63ZZ0, Q8VCR3, Q9NWH2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

22 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	13
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1047882	GRCh37/hg19 6q25.2-25.3(chr6:155308263-158394005)	Pathogenic

SpliceAI

714 predictions. Top by Δscore:

Variant	Effect	Δscore
6:157294167:C:CA	donor_gain	1.0000
6:157318780:A:AC	donor_gain	1.0000
6:157318781:C:CC	donor_gain	1.0000
6:157318781:CA:C	donor_gain	1.0000
6:157318781:CACT:C	donor_gain	1.0000
6:157319498:TCGCC:T	donor_gain	1.0000
6:157323407:CTTA:C	donor_loss	1.0000
6:157323410:ACCTT:A	donor_loss	1.0000
6:157292746:T:A	donor_gain	0.9900
6:157292997:CAT:C	acceptor_gain	0.9900
6:157293000:C:CC	acceptor_gain	0.9900
6:157294177:T:TA	donor_gain	0.9900
6:157318774:TTAC:T	donor_loss	0.9900
6:157318775:TAC:T	donor_loss	0.9900
6:157318776:AC:A	donor_loss	0.9900
6:157318777:C:CG	donor_loss	0.9900
6:157318778:TTAC:T	donor_loss	0.9900
6:157318779:TAC:T	donor_gain	0.9900
6:157318780:ACA:A	donor_gain	0.9900
6:157318780:ACAC:A	donor_loss	0.9900
6:157318781:C:CA	donor_loss	0.9900
6:157318781:CAC:C	donor_gain	0.9900
6:157318915:CTTCC:C	acceptor_gain	0.9900
6:157322700:CCAA:C	donor_loss	0.9900
6:157322702:AACC:A	donor_loss	0.9900
6:157322703:A:C	donor_loss	0.9900
6:157322704:CCTTA:C	donor_loss	0.9900
6:157322805:CCTG:C	acceptor_loss	0.9900
6:157322819:C:CT	acceptor_gain	0.9900
6:157322836:A:C	acceptor_gain	0.9900

AlphaMissense

900 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:157318815:G:C	S98R	0.997
6:157318815:G:T	S98R	0.997
6:157318817:T:G	S98R	0.997
6:157318838:A:G	W91R	0.989
6:157318838:A:T	W91R	0.989
6:157318835:A:G	C92R	0.983
6:157318873:G:T	A79D	0.983
6:157322756:A:C	F46L	0.983
6:157322756:A:T	F46L	0.983
6:157322758:A:G	F46L	0.983
6:157322711:G:C	F61L	0.981
6:157322711:G:T	F61L	0.981
6:157322713:A:G	F61L	0.981
6:157318840:G:T	A90E	0.979
6:157322773:C:G	G41R	0.977
6:157322773:C:T	G41R	0.977
6:157318825:C:T	G95D	0.976
6:157318853:C:G	G86R	0.975
6:157322781:G:T	A38D	0.975
6:157318852:C:T	G86D	0.973
6:157318831:C:T	G93E	0.972
6:157318826:C:G	G95R	0.971
6:157322772:C:T	G41E	0.971
6:157322791:C:G	G35R	0.971
6:157318828:A:T	V94D	0.968
6:157318858:C:T	G84D	0.968
6:157318850:A:G	S87P	0.967
6:157318861:A:T	L83Q	0.967
6:157322732:T:A	K54N	0.967
6:157322732:T:G	K54N	0.967

dbSNP variants (sampled 300 via entrez): RS1000187484 (6:157314394 T>A), RS1000245605 (6:157321419 T>C), RS1000314135 (6:157306942 A>G), RS1000647045 (6:157305587 A>G), RS1000767174 (6:157313405 A>C,G), RS1001382202 (6:157317912 A>G), RS1001612195 (6:157324062 G>A), RS1001673054 (6:157290967 T>C), RS1001766213 (6:157290674 G>A), RS1002190205 (6:157310001 G>A,C), RS1002237003 (6:157295563 G>C), RS1002248842 (6:157318283 G>A), RS1002318431 (6:157304273 C>T), RS1002419972 (6:157304080 A>C), RS1002658786 (6:157302793 C>A,T)

Disease associations

OMIM: gene MIM:620721 | disease phenotypes: MIM:217990

GenCC curated gene-disease

Mondo (2): cleft lip (MONDO:0004747), corpus callosum, agenesis of (MONDO:0009022)

Orphanet (1): Isolated corpus callosum agenesis (Orphanet:200)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0410030	Cleft lip

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST003127_7	Lipoprotein (a) levels	1.000000e-09
GCST007325_90	General risk tolerance (MTAG)	1.000000e-09
GCST009136_2	Ankle-brachial index	9.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0006925	lipoprotein A measurement
EFO:0008579	risk-taking behaviour
EFO:0003912	ankle brachial index

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D061085	Agenesis of Corpus Callosum	C10.500.034; C16.131.666.034; C23.300.008
D002971	Cleft Lip	C07.465.409.225; C07.465.525.164; C07.650.525.164; C16.131.850.525.164

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	4
Cadmium Chloride	decreases expression, increases abundance, increases expression	3
dicrotophos	decreases expression	1
quercitrin	increases expression	1
sodium arsenite	affects expression	1
cylindrospermopsin	increases expression	1
monomethylarsonous acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	increases abundance, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Folic Acid	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Methyl Methanesulfonate	increases expression	1
Nickel	decreases expression	1
Ozone	increases expression	1
Tretinoin	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

45 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03480607	PHASE4	COMPLETED	Dexmedetomidine as Adjuvant for Bupivacaine in Ultrasound Guided Infraorbital Nerve Block for Cleft Lip Repair
NCT00098319	PHASE3	COMPLETED	Oral Cleft Prevention Trial in Brazil
NCT00397917	PHASE3	COMPLETED	Oral Cleft Prevention Program
NCT03314090	PHASE3	COMPLETED	Silicone Gel in the Treatment of Cleft Lip Scars
NCT00004639	PHASE2	COMPLETED	Cleft Palate Surgery and Speech Development
NCT06885801	PHASE2	NOT_YET_RECRUITING	Evaluation of a Novel Nasal Conformer in Pediatric Patients
NCT01678105	PHASE2	COMPLETED	A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
NCT06066333	PHASE2	RECRUITING	Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
NCT06765837	PHASE1	COMPLETED	Comparison Between Low Level Laser Therapy and Active Oxygen Releasing Gel on Wound Healing Cleft Lip Patients
NCT01898715	PHASE1	COMPLETED	Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
NCT02247193	PHASE1/PHASE2	COMPLETED	Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair
NCT00070811	Not specified	COMPLETED	Assessing the Results of Lip Surgery in Patients With Cleft Lip and Palate
NCT00097149	Not specified	COMPLETED	Systematic Pediatric Care for Oral Clefts - South America
NCT00213889	Not specified	TERMINATED	TWIST Human Gene and Cleft Lips and Palates
NCT00285714	Not specified	UNKNOWN	3D Imaging of Hard and Soft Tissue in Orthognathic Surgery
NCT00340977	Not specified	COMPLETED	Svangerskap, Arv, Og Miljo (Pregnancy, Heredity and Environment)
NCT00829101	Not specified	COMPLETED	Articulation and Phonology in Children With Unilateral Cleft Lip and Palate
NCT00975208	Not specified	UNKNOWN	Osteogenesis and Dental Eruption Through Electrical Stimuli
NCT01252264	Not specified	COMPLETED	FaceBase Biorepository
NCT01380171	Not specified	COMPLETED	Primary Palatoplasty in Pediatric Patients - A Retrospective Review of Surgical Outcomes
NCT01601171	Not specified	RECRUITING	Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate
NCT02329509	Not specified	COMPLETED	Evaluation of Facial Growth in Two Primary Protocols Used in the Surgical Treatment of Unilateral Cleft Lip and Palate Patients
NCT02415361	Not specified	COMPLETED	Follow Ups of Parents With Infants With Cleft Lip and Palate
NCT02454998	Not specified	UNKNOWN	Alveolar Bone Grafting Outcome Between Patient With and Without Orthodontic Treatment
NCT02702869	Not specified	ENROLLING_BY_INVITATION	Allied Cleft & Craniofacial Quality-Improvement and Research Network (ACCQUIREnet)
NCT03029195	Not specified	COMPLETED	Nasoalveolar Molding for Egyptian Cleft Lip Palate Infants
NCT03537976	Not specified	ACTIVE_NOT_RECRUITING	Targeting Surgeons’ Decision-Making for Cleft Lip Surgery
NCT03572907	Not specified	WITHDRAWN	Use of Titanium Plate in Rhinoplasty in Patients With Cleft Lip and Palate : Aesthetic and Functional Impact.
NCT03839290	Not specified	UNKNOWN	Development of the Palate in Bilateral Orofacial Cleft Newborns One Year After Early Neonatal Cheiloplasty
NCT04277273	Not specified	COMPLETED	Characteristics of a Maxillofacial Prosthesis Consultation Within Assistance Publique - Hopitaux de Paris
NCT04334590	Not specified	WITHDRAWN	Fabrication of Sequential Naso-Alveolar Molding Appliances in the Treatment of Cleft Lip/Nose Deformities
NCT04627389	Not specified	UNKNOWN	Orbicularis Oris Z-plasty Modification of Modified Millard Technique and the Esthetic Outcome of Cleft Lip Repair
NCT04725370	Not specified	COMPLETED	Characterization of Cleft Lip and Palate Conditions in Guatemala
NCT05357092	Not specified	NOT_YET_RECRUITING	Effects of AlignBabyCleft (ABaCleft)
NCT05559281	Not specified	COMPLETED	Botulinum Toxin Injection in Reducing Lip Scar Following Cleft Lip Repair
NCT05748340	Not specified	COMPLETED	Unilateral Cleft Lip Repair : Modified Millard and Mishra Technique
NCT06411444	Not specified	NOT_YET_RECRUITING	Effect of Different Nasal Stent Designs With Nasoalveolar Molding Appliance
NCT07384338	Not specified	COMPLETED	Three Dimensional Evaluation of Dento-Skeletal Effects of Leaf Self Expander in Cleft Lip and Palate Patients
NCT01262235	PHASE1/PHASE2	COMPLETED	A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
NCT00170326	Not specified	COMPLETED	Progressive Ventricular Dysfunction Prevention in Pacemaker Patients